Clinical trials: Apixaban
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation, Periodontal Disease
Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
The purpose of this study is to evaluate the safety of a protocol which does not suspend the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Periodontal Disease, Hemorrhage
- Trial name
- NCT03181386
- Testing
- Rivaroxaban, Dabigatran and Apixaban, Warfarin
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- ASTER (NCT05171049)
- Testing
- Abelacimab, Apixaban
- Where
- 209 sites in United States, Australia and 19 more
- Volunteers
- 1,150 people
- Sponsor
- Anthos Therapeutics, Inc.
Venous Thromboembolism, Head and Neck Cancer
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery.
- Trial name
- NCT07189897
- Testing
- Enoxaparin, Apixaban
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Kiranya Arnold
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis
- Trial name
- NCT02585713
- Testing
- Apixaban, Dalteparin, Questionnaire Administration
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Academic and Community Cancer Research United
Atrial Fibrillation, Peritoneal Dialysis Complication
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
Introduction: Several randomised controlled trials have demonstrated that novel oral anticoagulants (NOACs) are safer compared to vitamin K antagonists for the management of non valvular atrial fibrillation (NVAF) to prevent…
- Trial name
- APIDP2 (NCT06045858)
- Testing
- Anticoagulation Agents
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Atrial Fibrillation, Venous Thromboembolism
The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)
Anticoagulants are used to prevent thrombotic events in patients with predisposing factors. However, the use of such therapies is associated with bleeding complications, which can be a serious safety issue.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- START-Portugal (NCT03977363)
- Testing
- Anticoagulant drugs
- Where
- Portugal
- Volunteers
- 25 people
- Sponsor
- CHAD
Atrial Fibrillation
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of…
- Trial name
- DARING-AF (NCT02666157)
- Testing
- Dabigatran etexilate, Rivaroxaban, Apixaban
- Where
- 5 sites in Taiwan
- Volunteers
- 3,672 people
- Sponsor
- National Cheng-Kung University Hospital
Stroke, Atrial Fibrillation
The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation
This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through…
- Trial name
- APIXABAN (NCT06864052)
- Testing
- Administration of Apixaban, Administration of Edoxaban
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Ewha Womans University Seoul Hospital
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Cirrhosis, Splenectomy
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461545
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Anticoagulation, Venous Thromboembolism
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay.
- Conditions
- Anticoagulation, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- UniXa (NCT04539301)
- Testing
- Estimated anticoagulant level (conversion factor x anti-Xa activity)
- Where
- France
- Volunteers
- 2,100 people
- Sponsor
- Nantes University Hospital
LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure
SWITCH: Apixaban vs Vitamin K in HM3
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced…
- Conditions
- LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding, Thrombosis; Artery
- Trial name
- NCT07471139
- Testing
- Warfarin, Apixaban
- Volunteers
- 460 people
- Sponsor
- Columbia University
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare…
- Trial name
- ADVANCE-2 (NCT00452530)
- Testing
- Enoxaparin, Apixaban
- Where
- 122 sites in Austria, Belgium and 25 more
- Volunteers
- 3,221 people
- Sponsor
- Bristol-Myers Squibb
Left Ventricular Thrombus, Acute Myocardial Infarction
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear.
- Trial name
- RESOLVE-AMI (NCT06515730)
- Testing
- Apixaban, Warfarin
- Where
- 16 sites in Sweden
- Volunteers
- 212 people
- Sponsor
- Karolinska Institutet
Deep Vein Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban…
- Trial name
- NCT00371683
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 3,608 people
- Sponsor
- Bristol-Myers Squibb
Cancer-associated Thrombosis
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with…
- Trial name
- API-CAT (NCT03692065)
- Testing
- Apixaban 5 MG
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 1,766 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Evaluate the Safety and Efficacy of Apixaban
A Multi-center Study of Apixaban(APPROACH)
The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid) postoperatively.
- Trial name
- NCT04550637
- Testing
- Oral apixaban
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Anticoagulation With Apixaban
Apixaban Validation Study - Additional Study on Fresh Samples
The objective is to demonstrate the performances of STA® - Apixaban Calibrator \& STA® - Apixaban Control used in combination with STA® - Liquid Anti-Xa to measure apixaban concentration in plasma.
- Trial name
- NCT03073265
- Testing
- STA-Apixaban Calibrator & Control
- Where
- 2 sites in United States
- Volunteers
- 109 people
- Sponsor
- Diagnostica Stago
Atrial Fibrillation
The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome
The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and…
- Trial name
- VALIANT-AF-S (NCT06953778)
- Testing
- Zio XT® Patch
- Where
- United States
- Volunteers
- 24,060 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development